Sanara MedTech Inc. Goodwill & Intangibles Disclosure
NOTE 5 – GOODWILL AND INTANGIBLES, NET
The changes in the carrying amount of the Company’s goodwill were as follows:
| Total | ||||
| Balance as of December 31, 2022 | $ | 3,601,781 | ||
| Acquisitions | ||||
| Balance as of December 31, 2023 | 3,601,781 | |||
| Acquisitions | ||||
| Balance as of December 31, 2024 | $ | 3,601,781 | ||
In connection with the change in reportable operating segments, the Company reassessed goodwill with respect to the change in reportable operating segments as they are presented in this report. Goodwill was recorded in connection with the acquisition of Scendia and is included entirely within the Sanara Surgical segment. The Company’s assessment determined that these changes, or any other matters noted, did not alter the Company’s conclusion that goodwill is not impaired as of December 31, 2024 or 2023.
The carrying values of the Company’s intangible assets were as follows for the periods presented:
| December 31, 2024 | December 31, 2023 | |||||||||||||||||||||||
| Cost | Accumulated Amortization | Net | Cost | Accumulated Amortization | Net | |||||||||||||||||||
| Amortizable Intangible Assets: | ||||||||||||||||||||||||
| Patents and Other IP | $ | 38,009,240 | $ | (5,008,856 | ) | $ | 33,000,384 | $ | 38,570,549 | $ | (3,181,186 | ) | $ | 35,389,363 | ||||||||||
| Customer relationships and other | 7,948,299 | (3,007,118 | ) | 4,941,181 | 7,947,332 | (1,861,887 | ) | 6,085,445 | ||||||||||||||||
| Product Licenses | 4,793,879 | (1,728,668 | ) | 3,065,211 | 4,793,879 | (1,342,626 | ) | 3,451,253 | ||||||||||||||||
| Total | $ | 50,751,418 | $ | (9,744,642 | ) | $ | 41,006,776 | $ | 51,311,760 | $ | (6,385,699 | ) | $ | 44,926,061 | ||||||||||
As of December 31, 2024, the weighted-average amortization period for finite-lived intangible assets was 14.6 years. Amortization expense related to intangible assets was $3,891,737 and $3,218,888 for the year ended December 31, 2024 and 2023, respectively. The estimated remaining amortization expense as of December 31, 2024 for finite-lived intangible assets is as follows:
| 2025 | $ | 3,894,221 | ||
| 2026 | 3,876,965 | |||
| 2027 | 3,763,113 | |||
| 2028 | 3,722,054 | |||
| 2029 | 3,722,054 | |||
| Thereafter | 22,028,369 | |||
| Total | $ | 41,006,776 |
The Company has reviewed the carrying value of intangible assets and has determined there was no impairment during the year ended December 31, 2024 or 2023.
Want the next Sanara MedTech Inc. goodwill & intangibles disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Sanara MedTech Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.